
InnoCare shares results from phase 2 trial for atopic dermatitis treatment
Betsy Goodfellow | December 18, 2023 | News story | Research and Development | Dermatology, InnoCare, atopic dermatitis, clinical trial
InnoCare Pharma has announced phase 2 clinical trial results for its novel TYK2 (tyrosine kinase 2) inhibitor, ICP-332, which met its primary endpoint in adult patients with moderate-to-severe atopic dermatitis (AD).
The trial assessed ICP-332 in AD patients for four weeks, throughout which it demonstrated a strong efficacy and safety profile, meeting multiple endpoints including Eczema Area and Severity Index (EASI) 50, EASI 75, EASI 90 (improvement of at least 50%, 75% and 90% in EASI score for baseline) and Investigator’s Global Assessment (IGA) 0/1 (score of 0 ‘clear’ or 1 ‘almost clear’) in both the 80mg and/or 120mg dosing groups.
The trial was a randomised, double-blind, placebo-controlled phase 2 trial which aimed to assess the safety, efficacy, pharmacokinetics and pharmacodynamics of ICP-332 in patients with moderate-to-severe AD.
The drug also demonstrated a strong safety and tolerability profile, with most treatment-related adverse events being mild to moderate.
Dr Jasmine Cui, the co-founder, chair and chief executive officer of InnoCare Pharma, commented: “AD has huge unmet medical needs and we are excited to see the positive results from the phase 2 study of ICP-332. We will further accelerate the clinical development to benefit patients with AD and other autoimmune diseases.”
Betsy Goodfellow
Related Content

SMC accepts atogepant for acute migraine treatment in Scotland
The Scottish Medicines Consortium (SMC) has accepted AbbVie’s Aquipta (atogepant) as an option for the …

Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …




